Multiple outlets discuss reported connections between the type 2 diabetes drug Mounjaro (tirzepatide) and pancreatic cancer, alongside broader concerns that pancreatic cancer mortality remains high and cases are rising. One source frames pancreatic cancer as a rapidly fatal disease, stating that about three-quarters of people diagnosed die within a year, and notes that incidence is increasing. The coverage also refers to a “landmark study” and discusses the potential impact of “fat jabs,” a term used for weight-loss and diabetes injections, on pancreatic cancer risk and outcomes. However, based on the provided article excerpts, specific study details—such as study design, population size, comparator groups, magnitude of risk change, and whether the findings are causal or associative—are not included. The information therefore reflects reported claims and general context about pancreatic cancer rather than a fully itemized evidence assessment. Overall, the sources converge on the same major themes: high mortality for pancreatic cancer, increasing incidence, and ongoing research into whether medications like Mounjaro affect pancreatic cancer risk or progression.